Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRiUM: AZD6738 and Gemcitabine in Advanced Solid Tumours
NCT03669601Phase 1Unknown
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Oct 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceralasertib in solid tumor and pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Cambridge Clinical Trials Unit. Primary endpoint: Dose Limiting Toxicity. Status: unknown.
02
Drugs
ceralasertib
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03669601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669601.